Myriad Genetics Plans Upcoming Fourth Quarter 2024 Results

Author: Kelly Martin Updated: 02-18-2025 08:49 AM

Myriad Genetics to Reveal Q4 and Full Year 2024 Results

Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in genetic and genomic tumor testing and precision medicine, is gearing up for its crucial fourth quarter and full year 2024 earnings conference call. The anticipated event is scheduled for February 24, 2025, at 4:30 PM ET. On this day, Myriad will share its financial results, offering vital insights into the company's overall performance significant to stakeholders.

Live Webcast and Participation

For interested parties, a live webcast of the earnings call will be accessible through Myriad’s Investor Relations website. Participants wishing to engage via telephone must pre-register for the conference call to receive a dial-in number and unique PIN. This event is a pivotal opportunity for investors to understand the company’s financial health and strategic direction.

Investor Conference Schedule

In addition to the earnings call, Myriad management has plans to participate in notable investor healthcare conferences. These engagements allow the company to connect directly with investors and industry leaders. Scheduled conferences include:

The TD Cowen 45th Annual Health Care Conference

Myriad's management will partake in a fireside chat at 9:50 AM ET on March 4, 2025.

The Raymond James 46th Annual Institutional Investors Conference

A formal presentation is set for 4:00 PM ET, also on March 4, 2025, where key insights and strategic initiatives will be discussed.

The Leerink Global Healthcare Conference

This event will feature Myriad's participation in a fireside chat at 2:20 PM ET on March 10, 2025, focusing on the latest advancements in the field of genetic testing.

About Myriad Genetics

Myriad Genetics has established itself as a leader in genetic and genomic tumor testing. The company is committed to enhancing health and well-being across diverse populations by providing innovative genetic testing solutions. Their tests are designed to assess the risk of potential diseases and aid in treatment decisions, exemplifying Myriad's dedication to personalized medicine.

Contact Information

For investor inquiries, please contact:

Matt Scalo
(801) 584-3532
IR@myriad.com

For media inquiries, please reach out to:

Kate Schraml
(224) 875-4493
PR@myriad.com

Frequently Asked Questions

What financial results will Myriad Genetics announce?

Myriad Genetics will disclose its earnings for the fourth quarter and full year 2024 during the February call.

When will the earnings call take place?

The earnings conference call is scheduled for February 24, 2025, at 4:30 PM ET.

How can I access the live webcast?

The webcast can be accessed on Myriad's Investor Relations website.

Who will be speaking at the investor conferences?

Management from Myriad will be speaking at various healthcare conferences throughout March, sharing updates and insights.

What is Myriad Genetics' main focus?

Myriad is focused on advancing the field of genetic testing and precision medicine to improve patient care.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.